A r t i c l e s
were from autosomes or the X chromosome. Genotype call rates were >99.9% in both datasets. The overdispersion factor of association test statistics, λ GC = 1.12, was similar to that observed in other GWASs of this sample size 7, 8 . Findings were not substantially altered by imputation of missing genotypes for 737 cases with celiac disease genotyped on the Hap300 BeadChip and corresponding controls ( Table 1 , collection 1). Here we present results for directly genotyped SNPs, as around half the additional Hap550 markers cannot be accurately imputed from Hap300 data 9 (including the new ETS1 locus reported in this study). Results for the top 1,000 markers are available in Supplementary Data 1; however, because of concerns regarding the detection of individuals' identities 10 , results for all markers are available only on request to the corresponding author.
For follow-up, we first inspected genotype clouds for the 417 non-HLA SNPs that met P GWAS < 10 −4 , being aware that top GWAS signals might be enriched for genotyping artifact, and excluded 22 SNPs from further analysis using a low threshold for possible bias. We selected SNPs from 113 loci for replication. Markers that passed design and genotyping quality control included (i) 18 SNPs from all 14 previously identified celiac disease risk loci (including a tag SNP for the major celiac disease-associated HLA-DQ2.5cis haplotype 1 ); (ii) 13 SNPs from all 7 newly discovered regions with P GWAS < 5 × 10 −7 ; (iii) 86 SNPs from 59 of 68 newly discovered regions with 5 × 10 −7 < P GWAS < 5 × 10 −5 in stage 1; and (iv) 14 SNPs from 14 of 30 newly discovered regions with 5 × 10 −5 < P GWAS < 10 −4 in stage 1 (for this last category, we mostly chose regions with immune system genes). Two SNPs were selected per region for regions with stronger association, regions with possible multiple independent associations and/or regions containing genes of obvious biological interest. We successfully genotyped 131 SNPs in 7 independent follow-up cohorts comprising 4,918 individuals with celiac disease and 5,684 control subjects of European descent ( Table 1 ). Genotype call rates were >99.9% in each collection. Primary association analyses of the combined GWAS and follow-up data were performed with a twosided 2 × 2 × 12 Cochran-Mantel-Haenszel test. Finally, we examined associated risk loci for cis expression-genotype correlations; a summary of subjects used for expression quantitative trait locus (eQTL) analyses is reported in Supplementary Table 1 .
Celiac disease risk variants
The HLA locus and all 13 other previously reported celiac disease risk loci showed evidence for association at a genome-wide significance threshold (P combined < 5 × 10 −8 ; Table 2 and Supplementary Fig. 1 ). We note that some loci were previously reported using less stringent criteria (for example, the P < 5 × 10 −7 recommended by the 2007 WTCCC study 11 ) ; however, in the current, much larger sample set, all known loci meet recently proposed P < 5 × 10 −8 thresholds 12, 13 . We identified 13 new risk regions with genome-wide significant evidence (P combined < 5 × 10 −8 ) of association, including regions containing the BACH2, CCR4, CD80, CIITA-SOCS1-CLEC16A, ETS1, ICOSLG, RUNX3, THEMIS, TNFRSF14 and ZMIZ1 genes, which have obvious immunological functions ( Table 2 and Supplementary Fig. 1) . A further 13 regions met 'suggestive' criteria for association (10 −6 > P combined > 5 × 10 −8 and/or P GWAS < 10 −4 and P followup < 0.01; Table 2 and Supplementary Fig. 1 ). These regions also contain multiple genes with immunological functions, including CD247, FASLG-TNFSF18-TNFSF4, IRF4, TLR7-TLR8, TNFRSF9 and YDJC. Six of the 39 non-HLA regions show evidence for the presence of multiple independently associated variants in a conditional logistic regression analysis (Supplementary Table 2) .
We tested the 40 SNPs with the strongest association ( Table 2 ) from each of the known genome-wide significant, new genome-wide significant and new suggestive loci for evidence of heterogeneity across the 12 collections studied. Only the HLA region was significant (Breslow-Day test P < 0.05 per 40 tests, rs2187668 P = 4.8 × 10 −8 ), which is consistent with the well-described North-South gradient in HLA allele frequency in European populations, and more specifically for HLA-DQ in celiac disease 14 . a Sample numbers attempted for genotyping, before any quality control (QC) steps were applied. b Sample numbers after all quality control (QC) steps (used in the association analysis). c All platforms contain a common set of Hap300 markers; the Hap550, 610-Quad, 670-Quad and 1.2M contain a common set of Hap550 markers. d As an additional quality control step, we performed case-case and control-control comparisons for collection 1 versus 2, and collection 3 versus 12, for the 40 SNPs in table 2 and observed no markers with P < 0.01. We did observe (as expected) differences for collection 5 versus 11, from northern and southern Italy, respectively. e All 737 post-QC cases reported in a previous GWAS 1 . f 690 of the post-QC cases and 1,150 of the post-QC controls were included in previous GWAS follow-up studies 22, 32 . g 498 of the post-QC cases and 767 of the post-QC controls were included in previous GWAS follow-up studies 22, 32 . h 352 of the post-QC cases and 921 of the post-QC controls were included in previous GWAS follow-up studies 22, 32 . i Some of these data were generated elsewhere, and some prior quality control steps (information not available) had been applied. j Finnish stage 2 controls were individuals within the Finrisk collection for whom Illumina 610-Quad genotype data became available after the completion of stage 1.
A r t i c l e s
We observed no evidence for interaction between each of the 26 genomewide significant non-HLA loci, which is consistent with what has been reported for other complex diseases so far. However, we did observe weak evidence for lower effect sizes at non-HLA loci in high risk HLA-DQ2.5cis homozygotes, similar to what has been observed in type 1 diabetes 7 .
To obtain more insight into the functional relatedness of the celiac disease risk loci, we applied GRAIL, a statistical tool that uses text mining of PubMed abstracts to annotate candidate genes from loci associated with common disease risk 15, 16 . To assess the sensitivity of this tool (using known loci as a positive control), we first a The most significantly associated SNP from each region is shown. b LD regions were defined by extending 0.1 cM to the left and right of the focal SNP as defined by the HapMap3 recombination map. All chromosomal positions are based on NCBI build-36 coordinates. c Minor allele in all samples in the combined dataset, odds ratios (shown for combined dataset) defined with respect to the minor allele in all controls. d Evidence from logistic regression at a genome-wide significant or suggestive level of significance after conditioning on other associated SNPs (see supplementary table 2 ). HLA region not tested, but previously known. e Selected named genes within or adjacent to the same LD block as the associated SNPs; causality is not proven. In particular, other genes and other causal mechanisms may exist. Gene names underlined are identified from GRAIL 15, 16 analysis (see Online Methods) with P text < 0.01. f These markers were present on the Hap550 but not Hap300 SNP sets, and are not genotyped for 737 cases and 2,596 controls in the stage 1 GWAS, and combined dataset analyses. Only minor changes in P values were observed when these genotypes were imputed and included in analysis. g The IRF4 region (specifically rs9738805, r 2 = 0.08 with rs1033180 in HapMap CEU) was previously identified as showing strong geographical differentiation 11 . Association with celiac disease was still observed after correction for population stratification using either a structured association approach 34 (corrected P GWAS = 5.16 × 10 −6 , 478 × 2 × 2 CMH test) or principal components correction (uncorrected P GWAS = 7.05 × 10 −6 , corrected P GWAS = 2.28 × 10 −5 , Cochran-Armitage trend tests combined using weighted Z scores; see Online Methods). However, definitive exclusion of population stratification would require family-based association studies.
performed a 'leave-one-out' analysis of the 27 genome-wide significant celiac disease loci (including HLA-DQ). GRAIL scores of P text < 0.01 were obtained for 12 of the 27 loci (44% sensitivity; Table 2 ).
Factors that limit the sensitivity of GRAIL include biological pathways being both known (a 2006 dataset is used to avoid GWAS-era studies) and published in the literature. We then applied GRAIL analysis, using the 27 known regions as a seed, to all 49 regions (49 SNPs) with 10 −3 > P combined > 5 × 10 −8 and obtained GRAIL P text < 0.01 for 9 regions (18.4%). As a control, only 5.5% (279 of 5,033) of randomly selected Hap550 SNPs reached this threshold. In addition to the five 
'suggestive' loci shown in Table 2 , GRAIL annotated four further interesting gene regions with lower significance in the combined association results: rs944141-PDCD1LG2 (P combined = 4.4 × 10 −6 ), rs976881-TNFRSF8 (P combined = 2.1 × 10 −4 ), rs4682103-CD200-BTLA (P combined = 6.8 × 10 −6 ) and rs4919611-NFKB2 (P combined = 6.1 × 10 −5 ). There appeared to be further enrichment for genes of immunological interest that are not GRAIL-annotated in the 10 −3 > P combined > 5 × 10 −8 significance window, including rs3828599-TNIP1 (P combined = 1.55 × 10 −4 ), rs8027604-PTPN9 (P combined = 1.4 × 10 −6 ) and rs944141-CD274 (P combined = 4.4 × 10 −6 ). Some of these findings, for which neither genome-wide significant nor suggestive association is achieved, are likely to comprise part of a longer tail of disease-predisposing common variants with weaker effect sizes. Definitive assessment of these biologically plausible regions would require genotyping and association studies using much larger sample collections than the present study. We previously showed that there is considerable overlap between risk loci for celiac disease and type 1 diabetes 17 , as well as between risk loci for celiac disease and rheumatoid arthritis 18 , and more generally, there is now substantial evidence for shared risk loci between the common chronic immune-mediated diseases 6 . To update these observations, we searched 'A Catalog of Published Genome Wide Association Studies' (accessed 18 November 2009) 19 and the HuGE database 20 . We found some evidence (requiring a published association report of P < 1 × 10 −5 ) of shared loci with at least one other inflammatory or immune-mediated disease for 18 of the current 27 genome-wide significant celiac disease risk regions. We defined shared regions as the broad linkage disequilibrium block; however, different SNPs are often reported in different diseases, and at only 3 of the 18 shared regions are associations across all diseases with the same SNP or a proxy SNP in r 2 > 0.8 in HapMap CEU. Currently, nine regions seem to be specific to celiac disease and might reflect distinctive disease biology, including the regions containing rs296547 and rs9792269 and the regions around CCR4, CD80, ITGA4, LPP, PLEK, RUNX3 and THEMIS. In fact, locus sharing between diseases is probably greater because of both stochastic variation in results from sample size limitations and regions that have a genuinely stronger effect size in one disease and weaker effect size in another.
Genetic variation in ETS1 has recently been reported to be associated with systemic lupus erythematosus (SLE) in the Chinese population, although it is not associated with SLE in European populations 21 . The most strongly associated celiac disease (European population) SNP, rs11221332, and the most strongly associated SLE (Chinese population) SNP, rs6590330, map 70 kb apart. Inspection of the HapMap phase II data shows broadly similar linkage disequilibrium patterns between Chinese (CHB) and European (CEU) populations in this region, with the two associated SNPs in separate nonadjacent linkage disequilibrium blocks. Thus, distinct common variants within the same gene can predispose to different autoimmune diseases across different ethnic groups.
Exploring the function of celiac disease risk variants
Celiac disease risk variants in the HLA genes alter protein structure and function 4 . However, we identified only four nonsynonymous SNPs with evidence for association with celiac disease (P GWAS < 10 −4 ) from the other 26 genome-wide significant associated regions (rs3748816-MMEL1, rs3816281-PLEK, rs196432-RUNX3, rs3184504-SH2B3). Although comprehensive regional resequencing is required to test the possibility that coding variants contribute to the observed association signals, more subtle effects of genetic variation on gene expression are the more likely functional mechanism for complex disease genes. With this in mind, we performed a meta-analysis of new and published genome-wide eQTL datasets comprising 1,469 human whole blood (PAXgene) samples reflecting primary leukocyte gene expression. We applied a new method, transcriptional components, to remove a substantial proportion of inter-individual nongenetic expression variation and performed eQTL meta-analysis on the residual expression variation (Online Methods).
We assessed 38 of the 39 genome-wide significant and suggestive celiac disease-associated non-HLA loci ( Table 2) for cis expressiongenotype correlations. We tested the SNP with the strongest association from each region. However, for five regions the most associated SNP was not genotyped in the eQTL samples (Hap300 data); instead, for four of these, we tested a proxy SNP (r 2 > 0.5 in HapMap CEU). In addition, for six loci showing evidence of multiple independent associations in conditional regression analyses, we tested a second SNP that showed independent association with celiac disease for eQTL analysis. In total, we assessed 44 independent non-HLA SNP associations in peripheral whole blood samples genotyped on the Illumina Hap300 BeadChip and either Illumina Ref8 or HT12 expression arrays, correlating each SNP with data from gene probes mapping within a 1-Mb window.
We identified significant (Spearman P < 0.0028, corresponding to 5% false-discovery rate) eQTLs at 20 of 38 (52.6%) non-HLA celiac loci tested (Table 3 and Supplementary Figs. 2 and 3) . Some loci had evidence of eQTLs with multiple probes, genes or SNPs ( Table 3) . We assessed whether the number of SNPs with cis-eQTL effects out of the 44 SNPs that we tested was significantly higher than expected. On average, eQTL SNPs had a substantially higher minor allele frequency (MAF) than non-eQTL SNPs in the 294,767 SNPs tested. To correct for this, we selected 44 random SNPs that had an equal MAF distribution and determined for how many of these MAF-matched SNPs eQTLs were observed. There were a significantly higher number of eQTL SNPs (P = 9.3 × 10 −5 , 10 6 permutations) among the celiac disease-associated SNPs than expected by chance (22 observed eQTL SNPs versus 7.8 expected eQTL SNPs). Therefore, the celiac diseaseassociated regions are greatly enriched for eQTLs. These data indicate that some risk variants might influence celiac disease susceptibility through a mechanism of altered gene expression. Candidate genes with a significant eQTL where the peak eQTL signal and peak casecontrol association signal are similar (Supplementary Fig. 3) include MMEL1, NSF, PARK7, PLEK, TAGAP, RRP1, UBE2L3 and ZMIZ1.
We also assessed the coexpression of genes that mapped within 500 kb of SNPs that showed the strongest case-control association from the 40 genome-wide significant and suggestive celiac disease loci in an analysis of the 33,109 human Affymetrix Gene Expression Omnibus dataset. This analysis loses power to detect tissue-specific correlations from the use of numerous tissue types, but it greatly gains power from the large sample size. We detected several distinct coexpression clusters (Pearson correlation coefficient between genes >0.5), including four clusters of immune-related genes that contain at least one gene from 37 of the 40 genome-wide significant and suggestive loci (Fig. 1) . These data further demonstrate that genes from celiac disease risk loci map to multiple distinct immunological pathways involved in disease pathogenesis.
DISCUSSION
We previously reported that most celiac genetic risk variants mapped near genes that are functional in the immune system 22 , and this remains true for the 13 new genome-wide significant and 13 new suggestive risk variants from the current study. We can now refine A r t i c l e s these observations and highlight specific immunological pathways that are relevant to the pathogenesis of celiac disease.
One key pathway worth highlighting is T-cell development in the thymus. The rs802734 linkage disequilibrium block contains the recently identified gene THEMIS (thymus-expressed molecule involved in selection). THEMIS has a key regulatory role in both positive and negative T-cell selection during late thymocyte development 23 . Furthermore, the rs10903122 linkage disequilibrium block contains RUNX3, a master regulator of CD8 + T lymphocyte development in the thymus 24, 25 . TNFRSF14 (LIGHTR, rs3748816 linkage disequilibrium block) has widespread functions in peripheral leukocytes and a crucial role in promoting thymocyte apoptosis 26 . The ETS1 transcription factor (rs11221332 linkage disequilibrium block) is also active in peripheral leukocytes; however, it is also a key player in thymic CD8 + lineage differentiation, acting in part by promoting RUNX3 expression 27 .
The importance of the thymus in the pathogenesis of autoimmune diseases has been previously emphasized by the established role of thymectomy in the treatment of myasthenia gravis. In type 1 diabetes, disease-associated genetic variation in the insulin gene INS causes altered thymic insulin expression and subsequent T-cell tolerance for insulin as a self-protein 28 . However, the importance of thymic T-cell regulation in the etiology of celiac disease has not been previously recognized. It is conceivable that the associated variants might alter biological processes before thymic MHC-ligand interactions. Alternatively, it is now clear that exogenous antigen presentation and selection occurs in the thymus through migratory dendritic cells; this has been demonstrated for skin and has been hypothesized for food antigens 29, 30 . These findings suggest that it would be worthwhile to investigate immunological and pharmacological modifiers of T-cell tolerance more generally in autoimmune diseases.
A second pathway worth noting is the innate immune detection of viral RNA. Although the association signal at rs5979785 (P combined = 6.36 × 10 −8 ) in the TLR7-TLR8 region is just outside our genomewide significance threshold, we observe a strong effect of rs5979785 on TLR8 expression in whole blood. Both TLRs recognize viral RNA. Taken together with the recent observation that rare loss-of-function mutations in the enteroviral response gene IFIH1 are protective against were analyzed from the HLA region; HLA-DQB2/HLA-DQB1 is a single expression probeset mapping to both genes. No probe for THEMIS was present on the earlier version of the U133 array; however, in a subset analysis of U133 Plus2.0 data, THEMIS is coexpressed in the major immune gene cluster.
A r t i c l e s type 1 diabetes 31 , these findings implicate viral infection (and the nature of the host response to infection) as a putative environmental trigger that could be common to these autoimmune diseases. A third pathway involves T-and B-cell co-stimulation (or coinhibition). This class of molecules controls the strength and nature of the response to T-cell or B-cell (immunoglobulin) receptor activation by antigens. We observe multiple regions with genes (CTLA4-ICOS-CD28, TNFRSF14, CD80, ICOSLG, TNFRSF9, TNFSF4) from this class of ligand-receptor pairs, indicating that fine control of the adaptive immune response might be altered in individuals at risk of celiac disease.
A final pathway involves cytokines, chemokines and their receptors. Our previous report discussed the function of the 2q11-12 interleukin receptor cluster (IL18RAP and so on), the 3p21 chemokine receptor cluster (CCR5 and so on) and the loci containing IL2-IL21 and IL12A 22 . We now report additional loci containing TNFSF18 and CCR4.
We estimate that the current celiac disease variants, including the major celiac disease-associated HLA variant, HLA-DQ2.5cis, less common celiac disease-associated haplotypes in the HLA (HLA-DQ8; HLA-DQ2.5trans; HLADQ2.2), and the additional 26 definitively implicated loci explain about 20% of total celiac disease variance, which would represent 40% of genetic variance, assuming a heritability of 0.5. A long tail of common variants with low effect size, along with highly penetrant rare variants (both at the established loci and elsewhere in the genome), might contribute substantially to the remaining heritability.
We observed different haplotypes within the ETS1 region associated with celiac disease in Europeans and SLE in the Chinese population. For some autoimmune diseases studied in European origin populations, although the same linkage disequilibrium block has been associated, the association is with a different haplotype. In some cases, the same variants are associated, but the direction of association is opposite (for example, rs917997-IL18RAP in celiac disease versus type 1 diabetes). We believe further exploration of these signals might reveal critical differences in the nature of the immune system perturbation between these diseases.
Previously, investigators have observed that only a small proportion of GWAS signals involve coding variants and have suggested that these variants might instead influence regulation of gene expression. Here we show that over half the variants associated with celiac disease are correlated with expression changes in nearby genes. This mechanism is likely to explain the function of some risk variants for other common, complex diseases. Further research is needed to definitively determine at each locus both the variants that can cause celiac disease and their functional mechanisms.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Accession numbers. Expression data are available in GEO (http:// www.ncbi.nlm.nih.gov/geo/) as GSE20142 and GSE20332.
Note: Supplementary information is available on the Nature Genetics website.
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